AU Comment: Doravirine The non-nucleoside reverse transcriptase inhibitor doravirine (DOR), was approved by the TGA in 2020 as a single drug or as a fixed dose combination with TDF and lamivudine (3TC). DOR/TDF/3TC is NOT reimbursed under the PBS in Australia. Table 9. Advantages and Disadvantages of Antiretroviral Components of Initial Antiretroviral Therapy Listed in …
This section has information on Management of the Treatment-Experienced Patient. Please click on the below links or follow the table of contents to access the information you are looking for. Virologic Failure Optimizing ART in the Setting of Virologic Suppression Poor CD4 Cell Recovery Discontinuation or Interruption of ARV
AU Comment: Australian Special Access Scheme for ARV treatments In heavily treatment-experienced patients, where treatment options are limited by drug resistance, toxicities or other issues, enrolment in a clinical trial of a new antiretroviral agent (if available), or use of an agent not yet TGA-approved for marketing but available through the Special Access Scheme, can …
AU Comment: Poor CD4 cell recovery and persistent inflammation despite viral suppression Current DHHS recommendations are suitable for implementation in Australia, including the following points: In individuals with viral suppression, adding ARV drugs or switching ARV drug classes does not consistently improve CD4 cell recovery or reduce all relevant markers of immune activation and is not …
Panel’s Recommendations for Optimizing Antiretroviral Therapy in the Setting of Virologic Suppression Key Considerations and Panel’s Recommendations Advances in antiretroviral (ARV) treatment and a better understanding of HIV drug resistance have made it possible to consider switching a person with HIV from an effective ARV regimen to an alternative ARV regimen in some situations The …
Optimising ART in the Setting of Virologic Suppression Read More »
AU Comment: Ibalizumab (IBA) Ibalizumab (IBA) a monoclonal antibody that is NOT PBS listed in Australia. Discontinuation or interruption of antiretroviral therapy (ART) may result in viral rebound, immune decompensation, and/or clinical progression.1-5 Thus, discontinuation or planned interruption of ART is not recommended outside the context of a clinical trial (AI). However, unplanned interruption of ART may …
This section has information on Special Patient Populations. Please click on the below links or follow the table of contents to access the information you are looking for. Women with HIV Substance Use Disorders and HIV HIV-2 Infection Early (Acute and Recent) HIV Infection Transgender People with HIV HIV and the Older Person Adolescents and …
AU Comment: Diagnosis of early HIV infection in Australia When acute HIV-1 infection is suspected, and an anti-HIV antibody and/or antibody/antigen combo test is negative or the western blot is indeterminate, other suitable test options include a nucleic acid test for HIV. However, proviral DNA tests are not widely available in Australia and HIV viral …
AU Comment: Adolescents and young adults with HIV in Australia In 2021, 4/745 (0.5%) of all new HIV notifications in Australia were among individuals aged 19 years or younger, with the majority (3/4) of these notifications among those aged 15-19 years. Reference: King J, McManus H, Kwon A, Gray A, McGregor S. HIV, viral hepatitis …
Developing a sustainable HIV, Viral Hepatitis and Sexual Health Workforce
Acknowledgement of Country
We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.
ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2024 ASHM